Low Level Laser Therapy: Energy density: 5 J/cm² Power: 0.1/0.5 W Course of treatment: 2 consecutive weeks, 5 days per week.
Alpha Lipoic Acid: Dosage: 600-800 mg ALA Course of treatment: 2 consecutive weeks, 3 times per day
Study summary
The aim of this study was to evaluate the efficacy of photobiomodulation therapy and alpha-lipoic acid in the treatment of burning mouth syndrome by symptom assessment with visual analogue scale.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Adults aged 18 to 75 years
* Diagnosis of Burning Mouth Syndrome (BMS) according to the 3rd edition of the International Classification of Headache Disorders (ICHD-3)
* Daily intraoral burning or dysesthesia lasting for more than 2 hours for over 3 months
* Normal oral mucosa and sensory testing
* Condition not better accounted for by another ICHD-3 diagnosis
Exclusion Criteria:
* Other oral mucosal diseases, such as oral leukoplakia or oral lichen planus
* Diabetes with poor blood glucose control
* Hematological diseases
* Pregnancy or lactation
* Severe mental disorders preventing cooperation with treatment
* Heart failure (New York Heart Association class III-IV)
Primary outcome measure(s)
Visual Analogue Scale (VAS) — Baseline and 2 weeks after intervention or observation The Visual Analogue Scale (VAS) will be used to assess the intensity of the patient's pain. The scale ranges from 0 to 10, where 0 represents "no pain" (the best possible outcome) and 10 represents "the worst pain imaginable" (the worst possible outcome). Therefore, higher scores indicate a worse outcome (greater pain intensity). During the interview or telephone follow-up, the patient will be asked to report the number that best describes their pain.
Trial sites (1)
Facility
City
Region
Status
West China Hospital of Stomatology, Sichuan University
Chengdu
Sichuan
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.